University of Medicine and Pharmacy, Department of Interdisciplinarity-Palliative Care Nursing , Grigore T Popa Iasi, 16 Universitatii Str, Iasi 700115 , Romania
Expert Opin Investig Drugs. 2013 Nov;22(11):1453-64. doi: 10.1517/13543784.2013.836489. Epub 2013 Sep 12.
Various compounds are developed to interfere with pathogenic pathways involved in inflammation processes. Some of them are able to enter the clinical development for different diseases with a common pathogenic denominator such as, for example, rheumatoid arthritis and chronic obstructive pulmonary disease (COPD), based on the preclinical evidence, but not all these molecules prove to be efficacious while tested in different phases of clinical development.
This review discusses about the drugs that were discontinued from further development for pulmonary, allergy, gastrointestinal and arthritis diseases
Most of the drugs discontinued during 2012 were compounds with anti-inflammatory activity which were mostly designed to treat arthritis/rheumatoid arthritis. Some of these molecules were also intended for COPD. Many of them failed the late phases of the clinical development.
为了干预炎症过程中的致病途径，人们研发了各种化合物。其中一些化合物基于临床前证据，已经进入了不同疾病（例如类风湿关节炎和慢性阻塞性肺疾病（COPD））的临床开发阶段。但并非所有这些分子在不同的临床开发阶段都被证明是有效的。
本文讨论了在 2012 年期间因肺部、过敏、胃肠道和关节炎疾病而被终止进一步开发的药物。
在 2012 年期间被终止开发的药物大多是具有抗炎活性的化合物，主要用于治疗关节炎/类风湿关节炎。其中一些分子也用于 COPD。它们中的许多药物在临床开发的后期阶段失败。
